Edition:
United Kingdom

Tracon Pharmaceuticals Announces Top-Line Data From Phase 2 Traxar Clinical Trial


Friday, 21 Dec 2018 

Dec 21 (Reuters) - TRACON Pharmaceuticals Inc ::TRACON PHARMACEUTICALS ANNOUNCES TOP-LINE DATA FROM PHASE 2 TRAXAR CLINICAL TRIAL IN RENAL CELL CARCINOMA.TRACON PHARMACEUTICALS INC - INLYTA DID NOT DEMONSTRATE CLINICALLY MEANINGFUL EFFICACY IN PATIENTS WITH ADVANCED OR METASTATIC RENAL CELL CARCINOMA.TRACON PHARMACEUTICALS INC - SAFETY PROFILE OBSERVED IN TRAXAR WAS CONSISTENT WITH PREVIOUS STUDIES OF TRC105.TRACON PHARMACEUTICALS - TRC105 IN COMBINATION WITH INLYTA DID NOT MEET PRIMARY ENDPOINT OF IMPROVING PROGRESSION FREE SURVIVAL IN STUDY.TRACON PHARMACEUTICALS - INTERIM ANALYSIS TO DETERMINE FINAL SAMPLE SIZE OF PHASE 3 TAPPAS TRIAL OF TRC105, VOTRIENT IN ANGIOSARCOMA EXPECTED IN Q1 2019. 

Company Quote

0.5591
 --
18 Jul 2019